New progress and prospect of breast cancer bone metastasis research from mechanism to clinic

doi:10.19401/j.cnki.1007-3639.2022.02.009

Abstract

Abstract:

Bone metastasis is one of the most serious complications in advanced breast cancer patients. Severe osteodynia, pathological fracture and other complications in bone metastasis of breast cancer can seriously affect the quality of life and shorten life span. In recent years, with the further understanding of the mechanism of bone metastases and the cross-talk between tumor cells and bone microenvironment, development and application of many new effective drugs have made significant progress in the treatment of bone metastasis of breast cancer. This article reviewed the mechanism of bone metastasis of breast cancer and current treatment advances.

Key words: Breast cancer, Bone metastasis, Mechanism, Treatment

CLC Number:

R737.9

WANG Jiahui, JIANG Linlan, SHEN Zan. New progress and prospect of breast cancer bone metastasis research from mechanism to clinic[J]. China Oncology, 2022, 32(2): 172-176.

Figures/Tables 1

References 31

[1]	FERLAY J E M, LAM Breast cancer overtakes lung cancer in terms of number of new cancer cases worldwide[M]. 2021.
[2]	PANTEL K,, HAYES D F. Disseminated breast tumour cells: biological and clinical meaning[J]. Nat Rev Clin Oncol, 2018,15(3):129-131.
[3]	MAKHOUL I,, MONTGOMERY C O,, GADDY D, et al. The best of both worlds-managing the cancer, saving the bone[J]. Nat Rev Endocrinol, 2016,12(1):29-42.
[4]	WORTZEL I,, DROR S,, KENIFIC C M, et al. Exosome-mediated metastasis: communication from a distance[J]. Dev Cell, 2019,49(3):347-360.
[5]	GUO Y X,, JI X,, LIU J B, et al. Effects of exosomes on pre-metastatic niche formation in tumors[J]. Mol Cancer, 2019,18(1):39.
[6]	SUPAKUL S,, YAO K T,, OCHI H, et al. Pericytes as a source of osteogenic cells in bone fracture healing[J]. Int J Mol Sci, 2019,20(5):1079.
[7]	PANG X,, GONG K,, ZHANG X, et al. Osteopontin as a multifaceted driver of bone metastasis and drug resistance[J]. Pharmacol Res, 2019,144:235-244.
[8]	HOFBAUER L C,, BOZEC A,, RAUNER M, et al. Novel approaches to target the microenvironment of bone metastasis[J]. Nat Rev Clin Oncol, 2021,18(8):488-505.
[9]	DAS S,, CLÉZARDIN P,, KAMEL S, et al. The CaSR in pathogenesis of breast cancer: a new target for early stage bone metastases[J]. Front Oncol, 2020,10:69.
[10]	WU X Q,, LI F F,, DANG L, et al. RANKL/RANK system-based mechanism for breast cancer bone metastasis and related therapeutic strategies[J]. Front Cell Dev Biol, 2020,8:76.
[11]	LUO G J,, HE Y D,, ZHAO Q, et al. Immune cells act as promising targets for the treatment of bone metastasis[J]. Recent Pat Anticancer Drug Discov, 2017,12(3):221-233.
[12]	COLEMAN R E,, CROUCHER P I,, PADHANI A R, et al. Bone metastases[J]. Nat Rev Dis Primers, 2020,6(1):83.
[13]	WANG K Y,, GU Y,, LIAO Y H, et al. PD-1 blockade inhibits osteoclast formation and murine bone cancer pain[J]. J Clin Invest, 2020,130(7):3603-3620.
[14]	HARARI A,, GRACIOTTI M,, BASSANI-STERNBERG M, et al. Antitumour dendritic cell vaccination in a priming and boosting approach[J]. Nat Rev Drug Discov, 2020,19(9):635-652.
[15]	LIANG S,, ZHENG J,, WU W, et al. A robust nanoparticle platform for RNA interference in macrophages to suppress tumor cell migration[J]. Front Pharmacol, 2018,9:1465.
[16]	GEORGE C N,, CANUAS-LANDERO V,, THEODOULOU E, et al. Oestrogen and zoledronic acid driven changes to the bone and immune environments: potential mechanisms underlying the differential anti-tumour effects of zoledronic acid in pre- and post-menopausal conditions[J]. J Bone Oncol, 2020,25:100317.
[17]	SUN W T,, GE K,, JIN Y, et al. Bone-targeted nanoplatform combining zoledronate and photothermal therapy to treat breast cancer bone metastasis[J]. ACS Nano, 2019,13(7):7556-7567.
[18]	GNANT M,, PFEILER G,, STEGER G G, et al. Adjuvant denosumab in postmenopausal patients with hormone receptor-positive breast cancer (ABCSG-18): disease-free survival results from a randomised, double-blind, placebo-controlled, phase 3 trial[J]. Lancet Oncol, 2019,20(3):339-351.
[19]	COLEMAN R,, FINKELSTEIN D M,, BARRIOS C, et al. Adjuvant denosumab in early breast cancer (D-CARE): an international, multicentre, randomised, controlled, phase 3 trial[J]. Lancet Oncol, 2020,21(1):60-72.
[20]	JEONG H,, JEONG J H,, KIM J E, et al. Final results of the randomized phase 2 LEO trial and bone protective effects of everolimus for premenopausal hormone receptor-positive, HER2-negative metastatic breast cancer[J]. Int J Cancer, 2021.
[21]	XU J,, HIGGINS M J,, TOLANEY S M, et al. A phase Ⅱ trial of cabozantinib in hormone receptor-positive breast cancer with bone metastases[J]. Oncologist, 2020,25(8):652-660.
[22]	ZHENG H Q,, BAE Y J,, KASIMIR-BAUER S, et al. Therapeutic antibody targeting tumor- and osteoblastic niche-derived Jagged1 sensitizes bone metastasis to chemotherapy[J]. Cancer Cell, 2017, 32(6): 731-747.e6.
[23]	COSMAN F,, CRITTENDEN D B,, ADACHI J D, et al. Romosozumab treatment in postmenopausal women with osteoporosis[J]. N Engl J Med, 2016,375(16):1532-1543.
[24]	HESSE E,, SCHRÖDER S,, BRANDT D, et al. Sclerostin inhibition alleviates breast cancer-induced bone metastases and muscle weakness[J]. JCI Insight, 2019,4(9):e125543.
[25]	SPRAVE T,, VERMA V,, FÖRSTER R, et al. Randomized phase Ⅱ trial evaluating pain response in patients with spinal metastases following stereotactic body radiotherapy versus three-dimensional conformal radiotherapy[J]. Radiother Oncol, 2018,128(2):274-282.
[26]	SPRAVE T,, VERMA V,, FÖRSTER R, et al. Local response and pathologic fractures following stereotactic body radiotherapy versus three-dimensional conformal radiotherapy for spinal metastases - a randomized controlled trial[J]. BMC Cancer, 2018,18(1):859.
[27]	UENO N T,, TAHARA R K,, FUJII T, et al. Phase Ⅱ study of Radium-223 dichloride combined with hormonal therapy for hormone receptor-positive, bone-dominant metastatic breast cancer[J]. Cancer Med, 2020,9(3):1025-1032.
[28]	Study of radium-223 dichloride versus placebo and hormonal treatment as background therapy in subjects with bone predominant HER2 (human epidermal growth factor receptor 2) negative hormone receptor positive metastatic breast cancer[M].
[29]	KERNEL N N I. Testing the addition of radium therapy (radium-223 dichloride) to the usual chemotherapy treatment (paclitaxel) for advanced breast cancer spread to the bones[J]. Case Med Res, 2019.
[30]	LEI W,, DUAN R,, LI J B, et al. The IAP antagonist SM-164 eliminates triple-negative breast cancer metastasis to bone and lung in mice[J]. Sci Rep, 2020,10(1):7004.
[31]	LU Z H,, ZOU J L,, LI S, et al. Epigenetic therapy inhibits metastases by disrupting premetastatic niches[J]. Nature, 2020,579(7798):284-290.